To study the effect of Bailing Capsule(百令胶囊)combined with angiotensin Ⅱ receptor blocking agent resistance(ARB)class antihypertensive drugs in the treatment of diabetes nephropathy(DN)on serum levels of transforming growth factor-β(TGF-β)/Smad,p38 mitogen activated protein kinase(p38MAPK).
A total of 78 patients with DN admitted to the hospital from January 2020 to January 2022 were selected and divided into the control group(39 cases)and the observation group(39 cases)by random number method. The control group was given Candesartan Cilexetil Tablets and insulin. The observation group was added Belling Capsule on the basis of the control group,all of which were treated for 16 weeks. Before and after treatment,the levels of fasting plasma glucose(FPG),glycosylated hemoglobin(HbA1c),serum creatinine(SCr),urea nitrogen(BUN)and serum TGF-β,Smad1,Smad2,Smad3,p38MAPK,P-P38MAPK protein of two groups were compared. In addition,the adverse reaction incidence of the two groups were compared after treatment.
The total effective rate was 87.74% in the observation group,significantly higher than that(69.23%)in the control group(P<0.05). The levels of FPG,HbA1c,SCr and BUN in the observation group were significantly lower than those before treatment and those in the control group after treatment(P<0.05). The protein levels of TGF-β,Smad1,Smad2 and Smad3 after treatment in the observation group were significantly lower than those before treatment and those in the control group after treatment(P<0.05). The serum levels of p38MAPK,p-p38MAPK and p-p38MAPK/p38MAPK in the observation group after treatment were significantly lower than those before treatment and those in the control group after treatment(P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups(41.03% vs 33.33%,P>0.05).
Belling Capsule combined with ARB class antihypertensive drugs in the treatment of DN can play a significant role in lowering blood glucose and improving renal function,and also can regulate the protein levels of TGF-β/Smad and p38MAPK,without significantly increasing the adverse reactions of drug treatment,which is worthy of clinical promotion and use.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |